



For more information contact:

John L. Tonkinson, Ph.D., Chief Business Development Officer
DCN Dx
Main: +1-760-804-3886 | Mobile: +1-860-977-4012
jtonkinson@dcndx.com

FOR IMMEDIATE RELEASE

June 6, 2019

DCN Dx and QIAGEN Lake Constance Announce Rapid Testing Innovation Award

\$10,000 cash prize and recognition from the rapid point-of-care diagnostics industry

CARLSBAD, Calif.—DCN Dx and Qiagen Lake Constance are pleased to announce the second Rapid Testing Innovation Award. The award, which includes a cash prize of \$10,000, will be presented at the 2019 Advanced Lateral Flow Course in October. The award recognizes the best innovation in rapid point-of-care assays or the most creative application for rapid assays during the past year.

The Rapid Innovation Award incentivizes creativity and entrepreneurship. Areas of interest include rapid diagnostics focusing on human health; veterinary or environmental testing; biological, chemical or radiological defense; pharmaceutical manufacturing; food safety; and other challenges.

“We’re very excited to offer this award to the best and brightest in rapid point-of-care diagnostics development,” said Brendan O’Farrell, Ph.D., President at DCN Dx, the sponsoring organization. “This competition hopes to leverage cutting edge technology to help solve a variety of challenges across industries.”

Last year’s winner was RPS for its FebriDx technology, a rapid point-of-care test that helps reduce unnecessary use of antibiotics in acute febrile respiratory infection.

Full submission guidelines are available on <http://lateralflowcourse.com/innovation/>.

The Advanced Lateral Flow Course and its Innovation Award are sponsored by DCN Dx and Qiagen Lake Constance.

Since its founding more than 12 years ago, DCN Dx has been committed to furthering the rapid diagnostic test market through the continued evolution of technologies and applications related to lateral flow assays. For more information about DCN Dx, visit dcndx.com.

[QIAGEN Lake Constance GmbH](#), a subsidiary of QIAGEN N.V., develops and produces innovative optical measuring instruments and detection units for the fields of biotechnology, medical technology, diagnostics, veterinary, environment and industry. The easy to use original equipment manufacturer (OEM) products enable our customers to develop their final product, either a lateral flow technology or a nucleic acid-based / isothermal amplification assays device. The OEM product range includes the development and production of portable instruments for point-of-need testing. QIAGEN Lake Constance GmbH cooperates internationally with various institutes and research facilities with an additional focus on the system integration of microfluidic test formats.

###